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CC BY-NC-ND license (http://creativeAbstract Hashimoto’s thyroiditis (HT) is the most common endocrine disorder leading to hy-
pothyroidism. HT is characterized by the presence of elevated circulating antibodies, espe-
cially anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-Tg). In our study, we
aimed to reveal the effects of autoimmunity on health-related quality of life of euthyroid
HT patients. Patients who were admitted to the Adnan Menderes University Outpatient Clinic
were enrolled. The medical records of the patients were surveyed and their demographical
data were collected. By using communication data, the patients were invited to our clinic,
to inform them about our study and to fill out the health-related quality of life questionnaire.
A total of 84 euthyroid HT patients older than 18 years who completed the short form-36 ques-
tionnaire, were enrolled. As all patients were euthyroid, there was a significant negative cor-
relation between each domain score and the antibody levels, individually. Patients who had
higher anti-TPO and anti-Tg levels had significantly lower quality of life domain scores
(p < 0.001). There was statistically no significant correlation between the antibody levels
and thyroid function tests (p > 0.05). Additionally, all dimension scores were significantly high-
er both in the anti-Tg and anti-TPO negative groups, indicating a better quality of life than that
in the antibody positive groups. Our study revealed that higher thyroid antibody levels were
negatively correlated with life quality scores. Thus, patients who had higher anti-TPO and
anti-Tg levels had significantly lower quality of life domain scores. We believe that apart from
hypothyroidism, a high antibody level was one of the contributing factors for the development
of HT-associated symptoms, leading to a lower quality of life. Other probable contributing fac-
tors such as selenium deficiency, thyroid hormone fluctuation, and disease awareness should
keep in mind.
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Hashimoto thyroiditis (HT) is the most common endocrine
disorder leading to hypothyroidism. The disease is
considered to be the most common autoimmune disease.
HT is characterized by the presence of elevated circu-
lating antibodies to thyroid antigens, especially the anti-
thyroid peroxidase (anti-TPO) and anti-thyroglobulin
(anti-Tg) antibodies [1]. The disease is diagnosed by
clinical properties, presence of serum antibodies, and the
sonographic appearance of thyroid. Anti-TPO is consid-
ered to be the best serological marker for the diagnosis of
HT and is found positive in nearly 95% of the patients. It
has been shown that anti-TPO titers are positively corre-
lated with the number of thyroid-infiltrating lymphocytes
and with the sonographic hypoechogenicity degree of the
thyroid [2]. Anti-Tg antibodies are positive in nearly
60e70% of HT patients and are found to be positive in a
higher proportion of healthy people. They are less specific
and sensitive for HT when compared with anti-TPO anti-
bodies [3]. As the two antibodies are assessed together for
the diagnosis in daily practice, they correlate poorly. In
HT, anti-TPO levels are expected to be at higher titers
than anti-Tg levels [1].
The influence of a chronic disease on the everyday life of
a patient is very important. Health-related quality of life
(HRQoL) is ‘a general concept that implies an evaluation of
the impact of all aspects of life on the general well-being’
[4]. In other words, it is the subjective assessment of how a
medical situation affects the daily physical, emotional,
social functioning, and well-being of a person [5]. When
treating a chronic disorder such as HT, the HRQoL of the
patient may be damaged because of different contributing
factors. Concurrently with medical examinations,
measuring HRQoL in daily clinical practice may give
important information about patients with particular diffi-
culties, which may need support, and about the effects of
the treatment modalities or the patients’ emotional moods.
In the last decade especially, HRQoL has been one of the
main targets of chronic disease treatment.
The importance of HRQoL has also increasingly been
acknowledged for thyroid disorders by some recent studies
[6e9]. To date, hypothyroidism is thought to be the main
factor for the increased symptom load and decreased
quality of life. However, studies have revealed that thyroid
disorders affect HRQoL, independently of the thyroid
function status. Even in euthyroid patients HRQoL was also
found to be decreased [7]. From this point of view, we
aimed to reveal other contributing factors of decreased
quality of life.
It is known that thyroid dysfunctions and mood disor-
ders, especially depression, often exist together [10].
Autoimmunity in the thyroid gland, mostly anti-TPO, was
found to be closely linked with decreased quality of life and
a depressed mood [7,11]. However, there are conflicting
studies suggesting that there is no association [12].
In our present study, we aimed to reveal the effects of
autoimmunity on HRQoL of euthyroid HT patients.
Furthermore, to the best of our knowledge, this is the first
study assessing the impact of two antibodies, anti-TPO and
anti-Tg together on HRQoL.Materials and methods
Study design
Patients with HT diagnosis who were admitted to Adnan
Menderes University Outpatient Clinic between December
2013 and January 2016 were enrolled in our study. The HT
diagnosis was based on histological validation or clinical
properties, presence of serum antibodies, and sonographic
findings. Among all selected participants, there were 13
patients with negative antibody but diagnosed with histo-
logical examination. The medical records of patients were
surveyed and the demographic data collected. Patients who
had thyroid function test results in the last 6 months and
thyroid antibody test results were selected. Normal ranges
in our laboratory for thyroid stimulating hormone (TSH) and
free thyroxine (fT4) were 0.35e4.94 IU/mL and
0.70e1.48 ng/dL, respectively. Patients who had hyper-
thyroidism (decreased TSH and increased fT4 levels) or
hypothyroidism (increased TSH and decreased fT4 levels)
were excluded. Patients with subclinical thyroid dysfunc-
tions were not included; only euthyroid patients were
included. Clinical variables including age, associating
chronic diseases, and treatment options were completed
during the survey. By using the communication data, pa-
tients were invited to our clinics to be informed about our
study and to fill out the HRQoL questionnaire. Written
informed consent of patients who agreed to participate in
the study was taken. Participants older than 18 years who
completed the SF-36 questionnaire were enrolled in the
study. Patients having psychiatric disorders, dementia,
pregnancy, inflammatory diseases, acute infections and
malignancy were excluded from the study. Additionally,
patients having mental or social retardation, who were
unable to complete the questionnaire, were also excluded.
This study was approved by the Ethics Committee of the
Adnan Menderes University Faculty of Medicine, Aydin,
Turkey.HRQoL measurement
SF-36 is a self-completed questionnaire measuring eight
aspects of health status: (1) physical functioning (PF)dthe
extent of health limiting physical activity; (2) physical role
playing (RP)dthe extent of physical health interfering or
limiting the usual role activities; (3) emotional role playing
(RE)dthe extent of emotional problems interfering or
limiting the usual daily role activities; (4) social functioning
(SF)dthe extent of physical health or emotional problems
interfering with the normal social activities; (5) bodily pain
(BP)dthe intensity of pain and effects on normal activities;
(6) mental health (MH)dincludes depression and anxiety;
(7) vitality (VT)dincluding feeling full of pep versus tired
and worn-out; and (8) general health (GH)dpersonal
evaluation of health. SF-36 measures these eight health
dimensions with 36 items: PF with 10 items; RP and VT each
with four items; RE with three items; SF and BP each with
two items; and GH and MH each with five items. There is a
further unscaled single item asking respondents about
health change over the past year. For each dimension, the
Table 1 Demographic and clinical characteristics of
patients.
Variable Value
Sex (female), n (%) 79 (94)
Patients with thyroid hormone
supplementation, n (%)
52 (62)
Patients with comorbidity,
n (%)
18 (21)
Age (y), mean  standard
deviation
41.82  12.16
TSH (mU/mL), median
(25the75th percentile)
1.89 (0.96e3.22)
fT4 (ng/dL), median
(25the75th percentile)
1.10 (0.99e1.19)
Anti-TPO (IU/mL), median 287.19 (22.72e762.20)
Quality of life in Hashimoto’s thyroiditis 429item scores are coded, summed, and transformed on to a
scale from 0 (worst possible health state measured by the
questionnaire) to 100 (the best possible health state) [13].
The scores represent the percentage of the total possible
score achieved. Following this, the items in the same scale
are averaged together to create the eight dimension scores.
Physical composite scores (PCS) and mental composite
scores (MCS) were calculated for the SF-36 as described by
Ware et al. [13,14]. PCS defines the general physical health
status and MCS defines the general mental health status.
The SF-36 questionnaire is widely used in chronically ill
patients and has significant correlations with other HRQoL
measures [14]. Moreover, adequate internal consistency
reliabilities (0.81e0.88) support its use [15]. The reliability
of the Turkish version of SF-36 has been proved by Koc¸yigit
et al. [16].(25the75th percentile)
Anti-Tg (IU/mL), median
(25the75th percentile)
24.82 (3.38e160.07)
Anti-Tg Z anti-thyroglobulin antibody; Anti-TPO Z anti-thyro-
peroxidase antibody; fT4 Z free thyroxine; TSH Z thyroid
stimulating hormone.Statistical analysis
All data were analyzed by using the PASW Statistics version
18 (SPSS Inc., Chicago, IL, USA) software package. The
KolmogoroveSmirnov test was used to assess the normality
of the numeric variables. Descriptive analyses were pre-
sented using the mean  standard deviation or median (25th
percentile to 75th percentile values) for continuous vari-
ables and percentage values were given for categorical
variables. Student t and ManneWhitney U tests were used
to compare the parametric continuous variables in the in-
dependent groups and Chi-square tests were used for the
comparison of categorical variables. The Spearman’s coef-
ficient was used to measure correlations among the quality
of life scores, the antibody levels, and thyroid function test
levels. Additionally, patients were stratified into groups
according to their serum antibody levels. Patients with
positive anti-TPO levels and negative anti-TPO levels were
assessed according to their HRQoL domain scores using the
ManneWhitney U test. Similar assessments were performed
according to the anti-Tg levels, too. An overall 0.05 type-1
error level was used to infer the statistical significance.Results
A total of 84 patients, 94% women and 6% men were
enrolled in our study. The mean age of the group was
41.82  12.16 years. The patient characteristics are pre-
sented in Table 1. Eighteen patients had additional
comorbidities except psychiatric disorders, dementia,
pregnancy, inflammatory diseases, acute infections, ma-
lignancy, and mental retardation. All patients had normal
fT4 and TSH levels within normal ranges. Fifty-two patients
(62% of the study population) were under thyroid hormone
supplementation. All patients with and without thyroid
hormone supplementation were euthyroid.
Overall, the HRQoL domain scores of the study population,
expressed as median (25the75th percentile) values, were as
follows: PF 80.00 (56.25e90.00); RP 50.00 (0.00e75.00); BP
62.00 (41.00e74.00); GH 43.50 (30.00e65.00); VT 32.50
(20.00e63.75); SF 50.00(37.50e75.00); RE 33.30 (0.00e
66.70); MH 52.00 (33.00e68.00); PCS 44.40 (36.57e51.22);
and MCS 34.55 (27.85e43.75).As shown in Table 2, there was a significant negative
correlation between each SF-36 domain score and antibody
level, individually. Patients who had higher anti-TPO and
anti-Tg levels had a significantly lower quality of life
domain scores (p < 0.001). There was no statistically sig-
nificant correlation between the antibody levels and thy-
roid function tests (p > 0.05). Additionally, there was no
significant correlation between the TSH or fT4 levels and
the HRQoL domain scores (p > 0.05).
Patients were stratified according to their antibody
levels. When anti-TPO positive patients were compared
with those with negative anti-TPO, no difference was found
in the prevalence in female patients [62 (94%) vs. 17 (94%),
p > 0.05] age and thyroid hormone supplementation [41
(62%) vs. 11 (61%), p > 0.05]. There was also no significant
difference in TSH [1.89 (0.98e3.32) vs.1.87 (0.93e2.96),
p > 0.05] and fT4 [1.09 (0.99e1.199 vs 1.14 (0.96e1.20),
p > 0.05] levels between anti-TPO positive and negative
groups. Similarly, there were no significant differences
between anti-Tg positive and negative groups in terms of
sex [56 (93%) vs. 23 (96%), p > 0.05], age, thyroid hormone
supplementation [37 (62%) vs. 15 (62%), p > 0.05], TSH
[1.89 (1.00e3.40) vs. 1.88 (0.92e2.75), p > 0.05] and fT4
[1.09 (0.99e1.19) vs. 1.10 (0.98e1.23), p > 0.05] levels. As
mentioned above, the groups were similar in terms of some
important probable confounding factors such as age, sex,
thyroid hormone supplementation and thyroid hormone
levels. All dimension scores were significantly higher both
in anti-Tg and anti-TPO negative groups, indicating a better
quality of life than in the antibody positive groups
(p < 0.001). When these groups were stratified by adjusting
the comorbidities as a confounding factor; there was also a
significant difference between both anti-TPO and anti-Tg
antibody positive and negative groups (p < 0.001). SF-36
domain scores in antibody positive and negative groups,
by adjusting comorbidities, are as presented in Tables 3
and 4.
Table 2 Relationship between health related quality of life scores and antibody levels by Spearman’s correlation coefficient.
PF RP BP GH VT SF RE MH PCS MCS
Anti-TPO 0.73* 0.76* 0.71* 0.69* 0.79* 0.55* 0.62* 0.68* 0.76* 0.64*
Anti-Tg 0.57* 0.65* 0.54* 0.65* 0.63* 0.51* 0.49* 0.56* 0.62* 0.56*
The Spearman’s coefficient was used to measure correlations. p < 0.05 was defined as statistically significant. * Correlation is significant
at the 0.01 level (2-tailed).
Anti-Tg Z anti-thyroglobulin antibody; Anti-TPO Z anti-thyroperoxidase antibody.
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It is well-known that thyroid dysfunction affects the mental
and physical dimensions of personal health and decreases
the HRQoL of patients [17]. Most of the studies point out
the presence of hypothyroidism and the related reduction
in the HRQoL of patients. However, euthyroid patients still
suffer from a general indisposition with various pre-
sentations. Our study clearly reveals that HT impacts the
perceived health status independently from the thyroid
function state. In the study by Demiral et al. [18], the
population norms of the SF-36 health survey in Turkey has
been determined. According to this Turkish norm-based SF-
36, the mean  standard deviation (median) dimension
scores are: PF 83.8  20.0 (100); RP 86.3  24.9 (100); BP
82.9  18.9 (100); GH 71.6  16.1 (72); VT 64.5  12.9 (70);
SF 91.0  12.9 (100); RE 90.1  19.4 (100); MH 71.0  11.0
(76); PCS 47.9  8.9 (54); and MCS 47.7  9.4 (52). When
compared with the Turkish general population norms, all
domains are evidently lower in our study group, indicating aTable 3 Health related quality of life (HRQoL) domain scores
levels by adjusting comorbidities.
Comorbidity HRQoL domain AntieTPO ()
Yes PF 92.50 (86.25e9
RP 100.00 (100.0e
BP 79.00 (74.00e8
GH 77.00 (64.50e8
VT 82.50 (72.50e8
SF 93.75 (78.12e1
RE 100.00 (100.00
MH 80.00 (73.00e8
PCS 53.15 (50.15e5
MCS 54.30 (52.15e5
No PF 95.00 (90.00e1
RP 100.00 (75.00e
BP 84.00 (74.00e1
GH 67.00 (57.00e7
VT 72.50 (60.00e8
SF 75.00 (59.37e1
RE 83.35 (58.35e1
MH 76.00 (63.00e8
PCS 54.05 (50.80e5
MCS 47.00 (43.20e5
*ManneWhitney U test, p < 0.05 was statistically significant. Data ar
BP Z bodily pain; GH Z general health; MCS Z mental composite
PF Z physical functioning; RE Z role emotional; RP Z role playing;poorer quality of life in HT patients. This poor HRQoL status
in euthyroid HT patients may have a few explanations. The
contributing factors may be disease awareness, subclinical
hypothyroidism, fluctuating thyroid hormone levels, and
antibody load, individually.
In some other chronic diseases such as hepatitis C, only
the awareness of the disease may lead to poorer HRQoL in
patients [19]. Therefore, solely the HT disease awareness
may be one of the contributing factors of poor HRQoL in our
patients.
The most relevant result of our study was the strong
association of both the higher anti-TPO and anti-Tg levels
with a lower HRQoL. In a few previous studies, a negative
correlation between HRQoL and anti-TPO has been
observed [7,20]. To the best of our knowledge this is the
first study demonstrating the negative correlation between
anti-Tg and HRQoL, entirely. Some researchers have
thought that if the antibody load itself is the main
impacting factor on the HRQoL, substantial reduction of the
antibody may help to improve the quality of life. It is knownin comparison with anti-thyroperoxidase antibody (Anti-TPO)
nZ 18 AntieTPO (þ) nZ 66 p*
8.75) 67.50 (27.50e86.25) 0.01
100.00) 25.00 (0.00e56.25) < 0.001
4.00) 41.00 (22.00e74.00) < 0.001
5.75) 42.00 (30.00e52.00) < 0.001
5.00) 27.50 (20.00e42.50) < 0.001
00.00) 56.25 (34.37e65.62) < 0.001
e100.00) 0.00 (0.00e33.30) < 0.001
4.00) 44.00 (32.00e56.00) < 0.001
5.70) 39.95 (28.05e47.00) 0.01
8.25) 32.90 (27.95e38.07) < 0.001
00.00) 70.00 (55.00e80.00) < 0.001
100.00) 25.00 (0.00e50.00) < 0.001
00.00) 57.00 (41.00e74.00) < 0.001
3.25) 40.00 (25.50e50.00) < 0.001
1.25) 25.00 (15.00e40.00) < 0.001
00.00) 50.00 (37.50e62.50) < 0.001
00.0) 33.30 (0.00e33.30) < 0.001
0.00) 46.00 (28.00e60.00) < 0.001
7.85) 40.95 (35.20e47.07) < 0.001
2.10) 32.25 (24.40e39.37) < 0.001
e reported as median (25the75th percentile).
scores; MH Z mental health; PCS Z physical composite scores;
SF Z social functioning; VT Z vitality.
Table 4 Health-related quality of life (HRQoL) domain scores in comparison with anti-thyroglobulin antibody (Anti-Tg) levels
by adjusting comorbidities.
Comorbidity HRQoL Domain Anti-Tg () nZ 24 Anti-Tg (þ) nZ 60 p*
Yes PF 90.00 (80.00e95.00) 55.00 (25.00e70.00) 0.01
RP 75.00 (50.00e100.00) 0.00 (0.00e25.00) < 0.001
BP 74.00 (57.50e84.00) 41.00 (22.00e51.50) 0.01
GH 62.00 (44.50e77.00) 40.00 (30.00e48.50) 0.03
VT 70.00 (37.50e 82.50) 20.00 (17.50e35.00) < 0.001
SF 75.00 (62.50e93.75) 50.00 (25.00e65.50) < 0.001
RE 100.00 (33.30e100.00) 0.00 (0.00e16.65) < 0.001
MH 72.00 (44.00e80.00) 40.00 (30.00e52.00) 0.02
PCS 50.90 (45.20e53.65) 39.60 (27.80e41.90) < 0.001
MCS 47.30 (34.95e54.30) 29.70 (25.85e36.15) < 0.001
No PF 95.00 (90.00e100.00) 70.00 (55.00e80.00) < 0.001
RP 100.00 (100.00e100.00) 25.00 (0.00e50.00) < 0.001
BP 100.00 (74.00e100.00) 52.00 (41.00e74.00) < 0.001
GH 72.00 (67.00e77.00) 40.00 (25.00e47.00) < 0.001
VT 75.00 (65.00e80.00) 25.00 (15.00e40.00) < 0.001
SF 75.00 (62.50e87.50) 50.00 (37.50e62.50) < 0.001
RE 66.70 (33.30e100.0) 33.30 (0.00e33.30) < 0.001
MH 76.00 (64.00e80.00) 48.00 (28.00e60.00) < 0.001
PCS 57.70 (54.00e59.90) 40.70 (35.00e46.20) < 0.001
MCS 47.40 (42.90e51.10) 32.20 (25.60e40.00) < 0.001
*ManneWhitney U test, p < 0.05 was statistically significant. Data are reported as median (25the75th percentile).
BP Z bodily pain; GH Z general health; MCS Z mental composite scores; MH Z mental health; PCS Z physical composite scores;
PF Z physical functioning; RE Z role emotional; RP Z role playing; SF Z social functioning; VT Z vitality.
Quality of life in Hashimoto’s thyroiditis 431that total or near total removal of the thyroid gland by
surgery leads to the reduction in antibody loads [21].
However, it was revealed by Promberger et al. [8] that
thyroidectomy is not a convenient option for increasing
HRQoL of HT patients, who have high anti-TPO antibody
levels. Additionally, after surgery, the lifelong overt hypo-
thyroidism and impaired immunity status should be
considered, as the quality of life may be further affected by
these factors.
As an autoimmune disease, numerous organ-specific and
nonorgan-specific diseases are known to associate with HT
[22]. These associating autoimmune diseases are thought to
be the contributing factors for the lower HRQoL scores in
HT. In the serum of patients with autoimmune thyroid dis-
ease there is a polyclonal immune response against some
autoantigens [23]. In light of these data, elevated serum
thyroid antibody levels may be seen as the representatives
of altered immunity. Consequently, removal of the thyroid
gland alone cannot improve the quality of life unless the
thyroid is the major stimulating factor for autoimmunity.
Dardano et al. [24] recently accounted for the possible role
of thyroid autoimmunity in the HT-associated clinical syn-
drome. They reported fibromyalgia in one-third of their HT
patients and fibromyalgia was higher in euthyroid patients.
Additionally, an electron microscopic study of the skeletal
muscles of euthyroid HT patients revealed alterations
indicating an association with thyroid autoimmunity and
muscle symptoms. This study implies that clinical course of
HT patients may be more complicated than it appears and
systemic autoimmunity triggered by thyroid antibodies maybe the key concept. In the study by Rotondi et al. [25], it
was revealed that antibody-negative HT patients have a
milder clinical course, with less overt hypothyroidism, as
compared to antibody-positive patients. Therefore, the
poor HRQoL of euthyroid patients with a positive antibody
makes it obvious that thyroid antibodies are the markers for
the consequent systemic autoimmune disease development
with numerous symptoms.
Thyroid hormones are essential in the nervous system
development and the thyroid hormone alterations may
lead to central nervous system malfunctions, such as
mood and cognition disorders [12]. In our study, the
mental dimensions in the SF-36 questionnaire, such as the
mental health and mental composite scores, are not
significantly correlated with the thyroid function tests.
Concurrently, euthyroid HT patients have also been asso-
ciated with the increasing risk of depression, depending
on the high anti-TPO levels [11,26]. Consistent with these
results, the mental health and mental composite scores
especially were found to be negatively correlated with
both the anti-Tg and anti-TPO levels, in our study. Pa-
tients with higher antibody levels were found to have a
lower HRQoL.
Nearly, 62% of the patients were under thyroid hormone
supplementation, in both the antibody negative and pos-
itive groups. It is well known that the thyroid hormone
levels frequently fluctuate in HT patients and the adjust-
ment of hormone supplementation may often be difficult
[7]. Thus, the idea that patients with higher antibody
levels may have experienced temporary hypothyroidism
432 H. Bektas Uysal, M. Ayhanmuch more than antibody-negative patients cannot be
denied. This may be another contributing factor of the
lower HRQoL scores in patients with higher antibody
levels.
Selenium is another noteworthy subject in HT patients.
Selenium deficiency is known to be associated with
increased risk of cancer and infections and serious neuro-
logical diseases such as Alzheimer’s and Parkinson’s dis-
ease. Additionally, selenium deficiency has also been shown
to contribute to mood changes, behavior, and cognitive
function alterations in HT patients [27,28]. After selenium
supplementation, a decrease in anti-TPO levels was
revealed by Ga¨rtner et al. [29]. Selenium is thought to
affect body immune responses directly by incorporation
into some selenoproteins [30]. Therefore, selenium may be
a treatment option for HT patients. However, further
studies are needed in this area.
In conclusion, our study revealed that higher antibody
levels are negatively correlated with quality of life scores.
Thus, patients who have higher anti-TPO and anti-Tg levels
have significantly lower quality of life domain scores. As all
our HT patients were euthyroid, the thyroid hormone sup-
plementation rates were similar in each group. We believe
that apart from hypothyroidism, a high antibody level is one
of the contributing factors for the development of HT-
associated symptoms leading to a lower quality of life.
Other probable contributing factors such as selenium defi-
ciency, thyroid hormone fluctuation, and disease awareness
must also be kept in mind. Further studies are needed to
pave the way for new approaches and treatment strategies
for HT patients.Acknowledgments
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